Associations of Stromal Markers' Expression in Benign Breast Tissue With Subsequent Breast Cancer Risk.
Researchers
Lusine Yaghjyan, Yujing J Heng, Maisey Ratcliffe, Yaileen D Guzman-Arocho, Laura C Collins, Bernard A Rosner, Rulla M Tamimi
Abstract
Breast stroma may play an important role in carcinogenesis. We examined the associations of stromal markers alpha-smooth muscle actin (αSMA), tenascin-C (TNC), fibroblast activation protein (FAP), calcyclin (s100a6), and matrix metallo-proteinase (MMP14) in benign breast biopsy samples with subsequent breast cancer (BCa) risk. This study included women with biopsy-confirmed benign breast disease (BBD) from a nested case-control study within the Nurses' Health Study (NHS) and NHSII cohorts. The data on BCa risk factors were obtained from questionnaires updated biennially. Multiplex immunofluorescence (IF) of stromal markers was completed on tissue microarrays. For each core, the percent (%) positivity was quantified using inForm v2.6.0. Multivariate logistic regression was used to examine the associations of each marker's expression (continuous and binary with 1% cutoff) with BCa risk, while adjusting for BCa risk factors. Among the 370 women (82 cases/288 controls), 106 (28.7%) had non-proliferative BBD, 205 (55.4%) had proliferative BBD without atypia, and 59 (16.0%) had proliferative BBD with atypia. We found suggestive evidence of positive associations of FAP expression with BCa cancer risk (OR per 10% change in expression = 1.15, 95% CI: 0.98-1.35). The expression of αSMA, s100a6, TNC, and MMP14 was not associated with subsequent BCa risk. In secondary models adjusting for BBD subtype and % mammographic breast density, these results remained similar. Our findings suggest that increased stromal fibroblast activation (as captured by FAP expression) may be associated with greater subsequent BCa risk. Further studies are needed to confirm these findings.Source: PubMed (PMID: 43049729)View Original on PubMed